529 692
References
[1]
Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European cancer observatory. Eur J Cancer 2015;51:1164–87.[2]
Cremers RG, Karim-Kos HE, Houterman S, et al. Prostate cancer: Trends in incidence, survival and mortality in The Netherlands, 1989-2006. Eur J Cancer 2010;46:2077–87.
[3]
Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate- cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8.
[4] European Association of Urology. European Association of Urology
Guidelines on Prostate Cancer. 2013.
http://www.uroweb.org/gls/ pdf/09_Prostate_Cancer_LR.pdf.
[5]
Heijmink SW, van Moerkerk H, Kiemeney LA, Witjes JA, Frauscher F, Barentsz JO. A comparison of the diagnostic performance of sys- tematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol 2006;16:927–38.[6]
Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men. J Urol 2000;163:1144–8, discussion 1148-9.
[7]
Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007;99:1395–400.[8]
Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and down- grading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grad- ing system and factoring in tertiary grades. Eur Urol 2012;61: 1019–24.[9]
Wu LM, Xu JR, Gu HY, et al. Usefulness of diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer. Acad Radiol 2012;19:1215–24.
[10]
Somford DM, Futterer JJ, Hambrock T, Barentsz JO. Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am 2008;16:685–95, ix.[11]
Pinto F, Totaro A, Calarco A, et al. Imaging in prostate cancer diagnosis: Present role and future perspectives. Urol Int 2011;86: 373–82.
[12]
Pinto F, Totaro A, Palermo G, et al. Imaging in prostate cancer staging: Present role and future perspectives. Urol Int 2012;88:125–36.[13]
Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746–57.
[14]
Barentsz JO, Weinreb JC, Verma S, et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imag- ing and recommendations for use. Eur Urol 2016;69:41–9.[15] European Society of Urogenital Radiology. PI-RADS v2 prostate
imaging and report and data system: Version 2.
http://www. esur.org/esur-guidelines/prostate-mri .[16]
Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–74.[17]
Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumours. A contemporary analy- sis. Cancer 2004;101:2001–5.
[18]
D’Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A. Outcome based staging for clinically localized adeno- carcinoma of the prostate. J Urol 1997;158:1422–6.
[19]
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localised prostate cancer. JAMA 1998;280:969–74.[20]
Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: A prospective study. J Urol 2014;192:67–74.[21]
Ahmed HU, Hu Y, Carter T, et al. Characterising clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011;186:458–64.[22]
Kasivisvanathan V, Dufour R, Moore CM, et al. Transperineal mag- netic resonance image targeted prostate biopsy versus transper- ineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol 2013;189:860–6.
[23]
Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by trans- rectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without pre- vious prostate biopsies. Eur Urol 2014;66:22–9.
[24]
Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281–5.[25]
Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: A sys- tematic review. Eur Urol 2013;63:125–40.[26]
Overduin CG, Futterer JJ, Barentsz JO. MRI-guided biopsy for pros- tate cancer detection: A systematic review of current clinical results. Curr Urol Rep 2013;14:209–13.[27]
Roethke MC, Kuru TH, Schultze S, et al. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol 2014;24(2):344–52.
[28]
Hoeks CM, Schouten MG, Bomers JG, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate- specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: Detection of clinically significant prostate cancers. Eur Urol 2012;62:902–9.[29]
Hadaschik BA, Kuru TH, Tulea C, et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 2011;186:2214–20.[30]
Rastinehad AR, Turkbey B, Salami SS, et al. Improving detection of clinically significant prostate cancer: magnetic resonance imaging/ transrectal ultrasound fusion guided prostate biopsy. J Urol 2014;191(6):1749–54.
[31]
Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guid- ed transperineal fusion biopsy for detection of prostate cancer. J Urol 2013;190:1380–6.[32]
Valerio M, Donaldson I, Emberton M, et al. Detection of clinically significant prostate cancer using magnetic resonance imaging- ultrasound fusion targeted biopsy: A systematic review. Eur Urol 2015;68:8–19.[33]
Labanaris AP, Engelhard K, Zugor V, Nutzel R, Kuhn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis 2010;13: 65–70.[34]
Puech P, Rouviere O, Renard-Penna R, et al. Prostate cancer diag- nosis: Multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy— prospective multicentre study. Radiology 2013;268:461–9.[35]
Booth A. Brimful of STARLITE’’: Toward standards for reporting literature searches. J Med Libr Assoc 2006;94:421–9, e205.[36]
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg 2010;8:336–41.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 1 7 – 5 3 1
529